Recruiting PHASE1/PHASE2 INTERVENTIONAL 6-arm NCT05024214

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

Envafolimab(KN035) in Combination With Lenvatinib in the Treatment of Advanced Solid Tumors: a Multicenter, Open-label, Phase Ib/II Study

Sponsor: 3D Medicines (Sichuan) Co., Ltd.

Conditions Hepatocellular Carcinoma Non-small Cell Lung Cancer Renal Cell Carcinoma Solid Tumors

Interventions Lenvatinib + Envafolimab Sunitinib

Updated 11 times since 2021 Last updated: May 27, 2025 Started: Nov 15, 2021 Primary completion: Dec 31, 2025 Completion: Dec 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Hepatocellular Carcinoma and Non-small Cell Lung Cancer and is currently actively recruiting participants. 3D Medicines (Sichuan) Co., Ltd. leads this study, which shows 11 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

11 versions recorded

Sep 2025 — Present [monthly]

Recruiting PHASE1/PHASE2
Jun 2025 — Sep 2025 [monthly]

Recruiting PHASE1/PHASE2
Sep 2024 — Jun 2025 [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Feb 2024 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2

▶ Show 6 earlier versions

May 2023 — Feb 2024 [monthly]

Recruiting PHASE1_PHASE2
Sep 2022 — May 2023 [monthly]

Recruiting PHASE1_PHASE2
Mar 2022 — Sep 2022 [monthly]

Recruiting PHASE1_PHASE2

Status: Not Yet Recruiting → Recruiting
Nov 2021 — Mar 2022 [monthly]

Not Yet Recruiting PHASE1_PHASE2
Oct 2021 — Nov 2021 [monthly]

Not Yet Recruiting PHASE1_PHASE2
Sep 2021 — Oct 2021 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

3D Medicines (Sichuan) Co., Ltd.

Data source: 3D Medicines

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijing, China , Bengbu, China , Changchun, China , Dalian, China , Dongguan, China , Fuzhou, China , Guangzhou, China , Haerbin, China , Hangzhou, China , Jinan, China and 10 more locations